These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2258162)

  • 41. Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis.
    Donati G; Piscaglia F; Colì L; Silvagni E; Righini R; Donati G; Pini P; Stefoni S; Bolondi L
    Aliment Pharmacol Ther; 2007 Sep; 26(5):717-26. PubMed ID: 17697205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of angiotensin II in hemodynamic responses to dynamic exercise in miniswine.
    Stebbins CL; Symons JD
    J Appl Physiol (1985); 1995 Jan; 78(1):185-90. PubMed ID: 7713810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Update on hepatorenal syndrome].
    Blaise P; Moonen M; Rorive G
    Nephrologie; 2002; 23(1):11-7. PubMed ID: 11887572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues.
    Weitzberg E; Ahlborg G; Lundberg JM
    Biochem Biophys Res Commun; 1991 Nov; 180(3):1298-303. PubMed ID: 1953780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Circulatory dysfunction syndrome associated with liver cirrhosis].
    Hartleb M
    Przegl Epidemiol; 2005; 59(2):549-58. PubMed ID: 16190566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 47. The hepatorenal syndrome.
    Moore K
    Clin Sci (Lond); 1997 May; 92(5):433-43. PubMed ID: 9176015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hepatorenal syndrome.
    Kiser TH; Maclaren R; Fish DN
    Pharmacotherapy; 2009 Oct; 29(10):1196-211. PubMed ID: 19792993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does local sympathetic atrophy contribute to splanchnic vasodilation in portal hypertension?
    Møller S; Stauber RE
    Liver Int; 2010 Apr; 30(4):499-501. PubMed ID: 20158609
    [No Abstract]   [Full Text] [Related]  

  • 50. Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.
    Di Pascoli M; Sacerdoti D; Pontisso P; Angeli P; Bolognesi M
    J Vasc Res; 2017; 54(2):92-99. PubMed ID: 28402977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyroid, renal, and splanchnic circulation in horses at rest and during short-term exercise.
    Manohar M; Goetz TE; Saupe B; Hutchens E; Coney E
    Am J Vet Res; 1995 Oct; 56(10):1356-61. PubMed ID: 8928955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathophysiology of portal hypertension.
    Bosch J; Pizcueta P; Feu F; Fernández M; García-Pagán JC
    Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatorenal syndrome.
    Guevara M; Rodés J
    Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical implications.
    Michielsen PP; Pelckmans PA
    Acta Gastroenterol Belg; 1994; 57(2):194-205. PubMed ID: 8053307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.
    Krag A; Bendtsen F; Henriksen JH; Møller S
    Gut; 2010 Jan; 59(1):105-10. PubMed ID: 19837678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nitric oxide-endothelin-1 interaction in humans.
    Ahlborg G; Lundberg JM
    J Appl Physiol (1985); 1997 May; 82(5):1593-600. PubMed ID: 9134909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Liver cirrhosis and cardiovascular system].
    Ponte E; Cafagna D
    Minerva Med; 1996 Jun; 87(6):299-310. PubMed ID: 8700359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatorenal syndrome: pathogenesis and novel pharmacological targets.
    Barada K
    Curr Opin Pharmacol; 2004 Apr; 4(2):189-97. PubMed ID: 15063365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatorenal syndrome.
    Guevara M; Ginès P
    Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.